Overview
INKT market data
Price History
INKT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.65 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.52 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.48 – $21.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $52.5 · P/B 6.29.
Company news
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyBenzinga · Jun 2, 2026, 2:15 PM
MiNK Therapeutics shares are trading higher. The company announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care vs placebo with SOC in patients with severe acute lung injury and critical illness.Benzinga · May 28, 2026, 3:22 PM
MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical IllnessBenzinga · May 28, 2026, 1:10 PM
MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026Benzinga · May 20, 2026, 3:15 PM
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price TargetBenzinga · May 18, 2026, 3:15 PM
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference CallBenzinga · May 15, 2026, 1:50 PM
8-K filing — MiNK Therapeutics, Inc. (INKT)SEC EDGAR · May 15, 2026, 12:03 PM
MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) EstimateBenzinga · May 15, 2026, 11:40 AM
MiNK Therapeutics Initiates Randomized Phase 2 Trial For agenT-797 In Severe Acute Lung Injury And Respiratory Distress, With Preliminary Data Expected In H2 Of 2026Benzinga · May 15, 2026, 11:40 AM
Earnings Scheduled For May 15, 2026Benzinga · May 15, 2026, 11:15 AM